KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial. PMID 39806375 · Cardiovasc Diabetol · 2025-Jan-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trials. PMID 39825757 · J Crohns Colitis · 2025-Jan-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. PMID 39804294 · J Crohns Colitis · 2025-Jan-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Young, Empowered & strong (YES): a study protocol paper for a randomized controlled trial of an mHealth symptom monitoring and self-management intervention for adolescent and young adult (AYA) breast cancer survivors. PMID 39799291 · BMC Public Health · 2025-Jan-11 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Obtaining personalized predictions from a randomized controlled trial on Alzheimer's disease. PMID 39799207 · Sci Rep · 2025-Jan-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Phase III Evaluation of Treatment Combinations in Three-Arm Trials. PMID 39467219 · J Clin Oncol · 2025-Jan-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy. PMID 39353164 · J Clin Oncol · 2025-Jan-10 This is a phase III randomized trial in oncology (low-risk cervical cancer) reporting original results. However, it does not meet two mandatory criteria: (1) the intervention is purely surgical (simple vs. radical hysterectomy) with no drug-containing arm, and (2) the primary outcomes reported are sexual health and quality of life (patient-reported outcomes), not a time-to-event efficacy endpoint such as overall survival, progression-free survival, or recurrence-free survival with Kaplan-Meier or hazard ratio analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. PMID 39353163 · J Clin Oncol · 2025-Jan-10 While the record describes an oncology, human, randomized, Phase III trial with a drug intervention and original results, it does not have a primary or key secondary time-to-event efficacy endpoint as required for inclusion in the KM digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. PMID 39788967 · Nat Commun · 2025-Jan-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Controlled Trial to Compare AmnioExcel Human Amniotic Allograft in Weekly Versus Biweekly Treatment of Diabetic Foot Ulcers. PMID 39784000 · Int J Low Extrem Wounds · 2025-Jan-09 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. PMID 39476124 · Blood · 2025-Jan-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. PMID 39316653 · Blood · 2025-Jan-09 The record describes a Phase III randomized trial with a time-to-event efficacy endpoint (EFS), but the provided abstract does not establish a drug-containing intervention as required for eligibility. The intervention described is treatment stratification based on risk classification, not the administration of a specific drug.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. PMID 39225259 · N Engl J Med · 2025-Jan-09 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. PMID 39780249 · Alzheimers Res Ther · 2025-Jan-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparative study between high and low dose methylene blue infusion in septic cancer patients: a randomized, blinded, controlled study. PMID 39780053 · BMC Anesthesiol · 2025-Jan-08 The trial is randomized and includes cancer patients, but the drug intervention (methylene blue) is for managing septic shock, not for treating the cancer. Therefore, it does not meet the criterion of a drug-containing intervention for oncology. The primary endpoint is also not a standard oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Anti-PD-1 and anti-PD-L1 antibodies for glioma. PMID 39777725 · Cochrane Database Syst Rev · 2025-Jan-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Patient experience with eosinophilic esophagitis symptoms and impacts on daily life based on in-trial qualitative interviews. PMID 39777591 · J Patient Rep Outcomes · 2025-Jan-08 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Statistical methods in the analysis of multicentre HIV randomized controlled trials in the African region: a scoping review. PMID 39773382 · BMC Med Res Methodol · 2025-Jan-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials. PMID 39354673 · Jpn J Clin Oncol · 2025-Jan-08 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Protocol digest of a phase III randomized trial of gross total resection versus possible resection of fluid-attenuated inversion recovery-hyperintense lesion on MRI for newly diagnosed supratentorial glioblastoma: JCOG2209 (FLAMINGO). PMID 39292165 · Jpn J Clin Oncol · 2025-Jan-08 The record is a protocol for a phase III randomized trial with a primary OS endpoint, but it lacks formal results and describes a surgical intervention, not a drug-containing one.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Challenges in multinational rare disease clinical studies during COVID-19: regulatory assessment of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease. PMID 39775064 · J Neurol · 2025-Jan-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design. PMID 39719420 · J Am Heart Assoc · 2025-Jan-07 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fatigue After Stroke Educational Recovery Program: A Prospective, Phase III, Randomized Controlled Trial. PMID 39719403 · J Am Heart Assoc · 2025-Jan-07 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravenous Lidocaine for Gut Function Recovery in Colonic Surgery: A Randomized Clinical Trial. PMID 39602290 · JAMA · 2025-Jan-07 The study is a randomized trial of a drug (lidocaine) in patients undergoing colon resection, but it is not an oncology trial focused on cancer outcomes. The primary endpoint is a composite measure of gut function recovery (GI-3), not a time-to-event oncology endpoint like OS, PFS, or DFS. While some patients had malignant disease, the trial is not primarily designed or powered for oncology efficacy. Therefore, it does not meet the inclusion criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Central ligation or partial preservation of the right gastric artery does not seem to affect conduit or anastomotic perfusion during robot-assisted resection of gastroesophageal junction cancer: a randomized clinical trial. PMID 39558692 · Dis Esophagus · 2025-Jan-07 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
First Measurement: Proactive Immune Cell Sparing in Radiation Therapy. PMID 39830271 · medRxiv · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of different intraoperative blood pressure regulation levels on postoperative myocardial injury in patients undergoing radical mastectomy for breast cancer after receiving neoadjuvant chemotherapy: a study protocol for a randomised controlled trial. PMID 39762100 · BMJ Open · 2025-Jan-06 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Home high-flow therapy during recovery from severe chronic obstructive pulmonary disease (COPD) exacerbation: a mixed-methods feasibility randomised control trial. PMID 39762067 · BMJ Open Respir Res · 2025-Jan-06 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer. PMID 39513948 · Clin Cancer Res · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery. PMID 39187984 · Cancer Prev Res (Phila) · 2025-Jan-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of hydrolyzed yeast on weanling pig growth performance, fecal dry matter, and stress-related blood antioxidant criteria. PMID 41002176 · J Anim Sci · 2025-Jan-04 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Supplemental effects of acidifier and encapsulated butyrate solely and combined in high canola meal diets for nursery pigs. PMID 40233213 · J Anim Sci · 2025-Jan-04 仅见动物/临床前证据,不是人体临床试验。
H
仅历史库存 excludednon_human pending 0 Figure · 0 Panel · risk -
Supporting endocrine therapy adherence in women with breast cancer: findings from the ROSETA pilot fractional factorial randomized trial. PMID 39887069 · Ann Behav Med · 2025-Jan-04 The study is a pilot/feasibility randomized trial for an intervention to improve endocrine therapy adherence, not a Phase III definitive efficacy trial. It does not report time-to-event efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of behavior change techniques to address barriers to follow-up colonoscopy: results from an online survey and randomized factorial experiment. PMID 39739614 · Ann Behav Med · 2025-Jan-04 The study is an online randomized factorial experiment testing behavior change techniques to increase colonoscopy follow-up intentions. While it is human, oncology-related, and randomized, it lacks a drug-containing intervention and does not report a time-to-event efficacy endpoint. It is therefore excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. PMID 39706209 · Lancet · 2025-Jan-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence. PMID 39847539 · JNCI Cancer Spectr · 2025-Jan-03 The record describes an observational cohort study, not a randomized trial of a drug intervention. Despite publication tags, the methods and abstract do not indicate a randomized trial of a therapeutic agent for cancer treatment or prevention with a time-to-event efficacy endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. PMID 39556192 · J Antimicrob Chemother · 2025-Jan-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial. PMID 39874036 · JAMA Netw Open · 2025-Jan-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Androgen Receptor Pathway Inhibitor Therapy for Advanced Prostate Cancer: Secondary Analysis of a Randomized Clinical Trial. PMID 39804646 · JAMA Netw Open · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Primary Mediastinal Ewing's Sarcoma: Post Hoc Analysis from Two International Multicenter Prospective Randomized Trials. PMID 39796745 · Cancers (Basel) · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Value of ctDNA in surveillance of adjuvant chemosensitivity and regimen adjustment in stage III colon cancer: a protocol for phase II multicentre randomised controlled trial (REVISE trial). PMID 39753246 · BMJ Open · 2025-Jan-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. PMID 39752157 · JAMA Netw Open · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial. PMID 39748312 · J Headache Pain · 2025-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. PMID 39321347 · Blood · 2025-Jan-02 The record describes a secondary analysis of two randomized trials. The original trials are not explicitly identified as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The analysis itself is a pooled secondary analysis, not the primary report of a definitive Phase III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Asundexian versus Apixaban in Patients with Atrial Fibrillation. PMID 39225267 · N Engl J Med · 2025-Jan-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. PMID 39213194 · N Engl J Med · 2025-Jan-02 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Role of precise management model in the maintenance of central venous indwelling catheters for cancer patients. PMID 40377613 · Indian J Cancer · 2025-Jan-01 The study is a randomized trial on catheter maintenance in cancer patients, but it does not meet the core eligibility criteria: it is not a drug intervention trial, does not report a time-to-event efficacy endpoint (like OS, PFS, etc.), and lacks a specified Phase III/IIIb or definitive phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Positron emission tomography versus computed tomography -guided intracavitary brachytherapy for locally advanced cervical cancer: A prospective randomized study. PMID 40214368 · J Cancer Res Ther · 2025-Jan-01 The trial is randomized and reports time-to-event efficacy endpoints (OS, LC) in human oncology patients. However, the randomized intervention is a radiotherapy planning/guidance technique (PET-CT vs. CT), not a drug-containing intervention versus control. Cisplatin is given concurrently to both arms as part of the standard chemoradiotherapy backbone, not as the variable under investigation. Therefore, it does not meet the requirement for a drug-containing intervention as the primary randomized comparison.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic Response. PMID 39853721 · Clin Transl Gastroenterol · 2025-Jan-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Empirical use of growth hormone in IVF is useless: the largest randomized controlled trial. PMID 39673334 · Hum Reprod · 2025-Jan-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -